FOR IMMEDIATE RELEASE:
CareMed Has Been Selected as a National Specialty Pharmacy Partner for Lecanemab-irmb (Leqembi®)
New Hyde Park, NY — October 29, 2024 — CareMed, the nation’s leading independent Specialty Pharmacy, has been selected by Eisai to be in the pharmacy network for Leqembi® (lecanemab-irmb). Leqembi is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta indicated for the treatment of Alzheimer’s disease. Treatment with Leqembi should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.1
“CareMed is grateful for the opportunity to become a specialty pharmacy provider for Leqembi”, said Benito Fernandez, Chief Commercial Officer. “We are proud to add another treatment option for patients with Alzheimer’s disease to our portfolio.”
The FDA approval of Leqembi is based on the results of the Phase III (NCT03887455) clinical trial, which compared Leqembi to placebo in patients 50 to 90 years of age with early Alzheimer’s disease. The study randomized 1795 patients in a 1:1 ratio to receive either intravenous Leqembi or placebo. The primary end point was the change from baseline at 18 months in the score on the Clinical Dementia Rating–Sum of Boxes (CDR-SB). The trial demonstrated an adjusted least-squares mean change from baseline at 18 months of 1.21 with Leqembi and 1.66 with placebo (difference, −0.45; 95% confidence interval [CI], −0.67 to −0.23; P<0.001).2
The most common adverse reactions (at approximately 10% and higher incidence compared to placebo) of Leqembi were infusion-related reactions, amyloid related imaging abnormality-microhemorrhages, amyloid related imaging abnormality-edema/effusion, and headache.1
Please see the full Prescribing Information for Leqembi®.
Media Contact: Benito Fernandez, Chief Commercial Officer
[email protected] | 516-640-1332
References:
- Leqembi Prescribing Information. Accessed October 2024.
Prescribing-Information.pdf (leqembi.com) - Van Dyck, C et al. Lecanemab in Early Alzheimer’s Disease. The New England Journal of Medicine. 2023; 388:9-21.